UA112679C2 - Заміщені хроманові сполуки як модулятори рецептора, чутливого до кальцію - Google Patents

Заміщені хроманові сполуки як модулятори рецептора, чутливого до кальцію Download PDF

Info

Publication number
UA112679C2
UA112679C2 UAA201410409A UAA201410409A UA112679C2 UA 112679 C2 UA112679 C2 UA 112679C2 UA A201410409 A UAA201410409 A UA A201410409A UA A201410409 A UAA201410409 A UA A201410409A UA 112679 C2 UA112679 C2 UA 112679C2
Authority
UA
Ukraine
Prior art keywords
methyl
ethyl
chroman
naphthalen
amino
Prior art date
Application number
UAA201410409A
Other languages
English (en)
Ukrainian (uk)
Inventor
Маноджкумар Рампрасад Шукла
Анкуш Гангарам САРДЕ
Раджешкумар Маганлал Лорія
Віпул Діліп Пашпуте
Навнат Баджірао Валке
Талха Хуссейн Кхан
Санджеев Анант Кулкарні
Венката П. Палле
Раджендер Кумар Камбодж
Original Assignee
Люпін Лімітед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Люпін Лімітед filed Critical Люпін Лімітед
Publication of UA112679C2 publication Critical patent/UA112679C2/uk

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/18Drugs for disorders of the endocrine system of the parathyroid hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/18Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cosmetics (AREA)
  • Pyrane Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
UAA201410409A 2012-02-24 2013-02-22 Заміщені хроманові сполуки як модулятори рецептора, чутливого до кальцію UA112679C2 (uk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN178KO2012 2012-02-24
IN1030KO2012 2012-09-07
PCT/IB2013/051445 WO2013124828A1 (en) 2012-02-24 2013-02-22 Substituted chroman compounds as calcium sensing receptor modulators

Publications (1)

Publication Number Publication Date
UA112679C2 true UA112679C2 (uk) 2016-10-10

Family

ID=54261188

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201410409A UA112679C2 (uk) 2012-02-24 2013-02-22 Заміщені хроманові сполуки як модулятори рецептора, чутливого до кальцію

Country Status (44)

Country Link
US (3) US9163001B2 (enExample)
EP (1) EP2817299B1 (enExample)
JP (1) JP6114316B2 (enExample)
KR (1) KR102041154B1 (enExample)
CN (1) CN104350047B (enExample)
AP (1) AP2014007919A0 (enExample)
AR (1) AR090135A1 (enExample)
AU (1) AU2013223715B2 (enExample)
BR (1) BR112014021133B1 (enExample)
CA (1) CA2864332C (enExample)
CL (1) CL2014002218A1 (enExample)
CO (1) CO7160018A2 (enExample)
CR (1) CR20140424A (enExample)
CU (1) CU24325B1 (enExample)
CY (1) CY1122017T1 (enExample)
DK (1) DK2817299T3 (enExample)
DO (1) DOP2014000193A (enExample)
EA (1) EA026940B9 (enExample)
ES (1) ES2743492T3 (enExample)
GE (1) GEP20186911B (enExample)
GT (1) GT201400179A (enExample)
HR (1) HRP20191606T1 (enExample)
HU (1) HUE046172T2 (enExample)
IL (1) IL234252A (enExample)
IN (1) IN2014MN01672A (enExample)
LT (1) LT2817299T (enExample)
MA (1) MA35937B1 (enExample)
MX (1) MX355670B (enExample)
MY (1) MY171374A (enExample)
NI (1) NI201400094A (enExample)
NZ (1) NZ628627A (enExample)
PE (1) PE20142281A1 (enExample)
PH (1) PH12014501891B1 (enExample)
PL (1) PL2817299T3 (enExample)
PT (1) PT2817299T (enExample)
RS (1) RS59172B1 (enExample)
SG (1) SG11201405117SA (enExample)
SI (1) SI2817299T1 (enExample)
SM (1) SMT201900506T1 (enExample)
TN (1) TN2014000352A1 (enExample)
TW (1) TWI617549B (enExample)
UA (1) UA112679C2 (enExample)
WO (1) WO2013124828A1 (enExample)
ZA (1) ZA201405990B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT201900506T1 (it) * 2012-02-24 2019-11-13 Lupin Ltd Composti cromanici sostituiti come modulatori dei recettori sensibili al calcio
AU2013308081A1 (en) * 2012-08-27 2015-02-26 Lupin Atlantis Holdings Sa Arylalkylamine compounds as calcium sensing receptor modulators
TW201602062A (zh) 2013-08-12 2016-01-16 魯賓有限公司 取代聯苯基化合物作為鈣敏感受體調節劑
WO2015028938A1 (en) 2013-08-28 2015-03-05 Lupin Limited Substituted naphthalene compounds as calcium sensing receptor modulators
WO2015162538A1 (en) 2014-04-21 2015-10-29 Lupin Limited Heterocyclic compounds as calcium sensing receptor modulators for the treatment of hyperparathyroidism, chronic renal failure and chronic kidney disease
WO2017037616A1 (en) 2015-08-31 2017-03-09 Lupin Limited Arylalkylamine compounds as calcium sensing receptor modulators
JP7764372B2 (ja) * 2019-11-19 2025-11-05 ルピン・リミテッド クロマン化合物を調製する方法
US20230049917A1 (en) * 2019-12-27 2023-02-16 Lupin Limited Pharmaceutical Composition of CASR Modulators and Methods and Uses Thereof
DK4090654T3 (da) * 2020-01-17 2025-09-08 Lupin Ltd Fremgangsmåder, processer og mellemprodukter til fremstilling af kromforbindelser
WO2025255092A1 (en) * 2024-06-03 2025-12-11 Artax Biopharma Inc. Combination of a chromene derivative tcr inhibitor and a tyk2 inhibitor

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0020018B1 (en) * 1979-05-19 1983-06-01 Beecham Group Plc Chroman derivatives, processes for their preparation and pharmaceutical compositions containing them
US5387587A (en) * 1986-12-23 1995-02-07 Merck Patent Gesellschaft Mit Beschrankter Haftung Chroman derivatives
US6133277A (en) 1997-12-05 2000-10-17 Janssen Pharmaceutica N.V. (Benzodioxan, benzofuran or benzopyran) derivatives having fundic relaxation properties
FR2809396B1 (fr) 2000-05-24 2005-10-14 Centre Nat Rech Scient Nouvelles molecules possedant une activite calcimimetique et leur mode de preparation
FR2812875B1 (fr) 2000-08-08 2003-12-12 Centre Nat Rech Scient Nouvelles diamines possedant une activite modulatrice des casr et leur mode de preparation
WO2004069793A2 (en) 2003-01-28 2004-08-19 Bristol-Myers Squibb Company Novel 2-substituted cyclic amines as calcium sensing receptor modulators
CA2527203C (en) 2003-05-28 2010-08-17 Japan Tobacco Inc. Casr antagonist
CA2608957C (en) 2005-05-19 2013-12-10 Astellas Pharma Inc. Pyrrolidine derivative or salt thereof
TW200815388A (en) 2006-04-18 2008-04-01 Wyeth Corp Chromane and chromene derivatives and uses thereof
CA2663436A1 (en) 2006-10-04 2008-04-10 Pfizer Products Inc. Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists
AU2007318092B2 (en) * 2006-10-26 2013-01-10 Amgen Inc. Calcium receptor modulating agents
US8153658B2 (en) 2006-11-16 2012-04-10 Astellas Pharma, Inc. Piperidine derivative or salt thereof
WO2009051718A2 (en) * 2007-10-15 2009-04-23 Amgen Inc. Calcium receptor modulating agents
NZ585543A (en) 2007-11-23 2012-08-31 Leo Pharma As Naphthalene-containing cyclic hydrocarbon compounds for the treatment of disturbances of calcium sensor receptor activity
KR101700152B1 (ko) 2008-10-03 2017-01-26 이에이 파마 가부시키가이샤 CaSR 효능제
US8791147B2 (en) 2008-10-08 2014-07-29 Amgen Inc. Calcium receptor modulating agents
WO2010136037A1 (en) 2009-05-27 2010-12-02 Leo Pharma A/S Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof
WO2010150837A1 (ja) 2009-06-25 2010-12-29 第一三共株式会社 インドリン誘導体
CN103270018A (zh) 2010-11-26 2013-08-28 利奥制药有限公司 钙敏感受体激活化合物
CN103391920A (zh) 2010-11-26 2013-11-13 利奥制药有限公司 钙敏感受体激活化合物
US20130267516A1 (en) 2010-11-26 2013-10-10 Leo Pharma A/S Substituted cyclopentyl-azines as casr-active compounds
WO2012120476A1 (en) 2011-03-10 2012-09-13 Lupin Limited Substituted morpholines as modulators for the calcium sensing receptor
AU2012232706B2 (en) 2011-03-18 2016-12-15 Lupin Atlantis Holdings Sa Benzo [b] [1, 4] oxazin derivatives as calcium sensing receptor modulators
SMT201900506T1 (it) * 2012-02-24 2019-11-13 Lupin Ltd Composti cromanici sostituiti come modulatori dei recettori sensibili al calcio

Also Published As

Publication number Publication date
JP2015508097A (ja) 2015-03-16
IN2014MN01672A (enExample) 2015-05-29
CU20140103A7 (es) 2015-01-29
MX355670B (es) 2018-04-25
IL234252A (en) 2017-02-28
EP2817299A1 (en) 2014-12-31
ZA201405990B (en) 2015-11-25
PL2817299T3 (pl) 2019-12-31
TN2014000352A1 (en) 2015-12-21
WO2013124828A1 (en) 2013-08-29
ES2743492T3 (es) 2020-02-19
SG11201405117SA (en) 2014-09-26
AP2014007919A0 (en) 2014-09-30
MA35937B1 (fr) 2014-12-01
US20150038546A1 (en) 2015-02-05
SMT201900506T1 (it) 2019-11-13
SI2817299T1 (sl) 2019-10-30
US20150368222A1 (en) 2015-12-24
CN104350047A (zh) 2015-02-11
US9598391B2 (en) 2017-03-21
CA2864332A1 (en) 2013-08-29
NZ628627A (en) 2017-02-24
CN104350047B (zh) 2017-05-24
BR112014021133B1 (pt) 2022-06-28
MX2014010139A (es) 2015-09-04
KR20140135731A (ko) 2014-11-26
CA2864332C (en) 2020-08-25
KR102041154B1 (ko) 2019-11-07
EP2817299B1 (en) 2019-06-12
EA026940B1 (ru) 2017-06-30
GT201400179A (es) 2016-03-01
CO7160018A2 (es) 2015-01-15
BR112014021133A2 (pt) 2018-09-11
GEP20186911B (en) 2018-10-25
PH12014501891A1 (en) 2015-02-09
RS59172B1 (sr) 2019-10-31
CL2014002218A1 (es) 2015-03-06
AU2013223715A1 (en) 2014-08-28
MY171374A (en) 2019-10-10
AR090135A1 (es) 2014-10-22
LT2817299T (lt) 2019-09-25
JP6114316B2 (ja) 2017-04-12
CR20140424A (es) 2015-01-13
EA201491582A1 (ru) 2014-12-30
PT2817299T (pt) 2019-09-23
AU2013223715B2 (en) 2017-09-14
PH12014501891B1 (en) 2021-05-05
HRP20191606T1 (hr) 2019-12-13
US9163001B2 (en) 2015-10-20
TW201336831A (zh) 2013-09-16
DK2817299T3 (da) 2019-09-16
DOP2014000193A (es) 2017-01-15
CU24325B1 (es) 2018-03-13
TWI617549B (zh) 2018-03-11
CY1122017T1 (el) 2020-10-14
US20170209410A1 (en) 2017-07-27
PE20142281A1 (es) 2015-01-16
HK1205117A1 (en) 2015-12-11
NI201400094A (es) 2015-03-27
HUE046172T2 (hu) 2020-02-28
EA026940B9 (ru) 2017-11-30
US9987249B2 (en) 2018-06-05

Similar Documents

Publication Publication Date Title
UA112679C2 (uk) Заміщені хроманові сполуки як модулятори рецептора, чутливого до кальцію
CN105330576B (zh) 二环芳基鞘氨醇1‑磷酸酯类似物
CN114206832B (zh) 拮抗lpa1受体的脲化合物
TWI439263B (zh) 胺化合物及其醫藥用途
EP3303293B1 (en) Ror-gamma modulators
FR2509297A1 (fr) Benzene-sulfonates organiques, leur preparation et compositions antilipemiques contenant ces substances
AU2006224295A1 (en) N- (N-sulfonylaminomethyl) cyclopropanecarboxamide derivatives useful for the treatment of pain
UA122591C2 (uk) Фенільні похідні як агоністи канабіноїдного рецептора 2
WO1992012144A1 (en) Condensed benzoxa ring compound, production thereof, and pharmaceutical composition containing the same
CN104583177B (zh) 作为钙敏感受体调节剂的芳基烷基胺化合物
JP2008534567A (ja) Vr1受容体アンタゴニストとしての置換アリールオキソエチルシクロプロパンカルボキサミド化合物
US5053399A (en) Myo-inositol analogs and methods for their use
EP3039014A1 (en) Substituted naphthalene compounds as calcium sensing receptor modulators
US4937390A (en) Compound useful for the production of 3-deoxy-3-fluoro-myo-inositol
EP0518904B1 (en) S-(2-thenoyl)-thiolactic acid derivative having pharmacological activity
OA17086A (en) Substituted chroman compounds as calcium sensing receptor modulators.
HK1205117B (en) Substituted chroman compounds as calcium sensing receptor modulators